American Journal of Psychiatry

Objective:Pharmacological treatments for agitation and aggression in patients with Alzheimer’s disease have shown limited efficacy. The authors assessed the heterogeneity of response to citalopram in the Citalopram for Agitation in Alzheimer Disease (...

https://doi.org/10.1176/appi.ajp.2015.15050648

pdf

abstract

full text

SAVE ARTICLE

Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer’s Dementia: Evidence From the CitAD Study

Publication date: 01 April 2016

Pages473–480

Objective:Citalopram has been shown to improve agitation in patients with Alzheimer’s disease. The authors evaluated whether other neuropsychiatric symptoms improve with citalopram treatment compared with placebo.Method:In this planned secondary analysis ...

https://doi.org/10.1176/appi.ajp.2016.15020248

Video

Divergent Outcomes in Cognitive-Behavioral Therapy and Pharmacotherapy for Adult Depression

Publication date: 12 February 2016

Pages481–490

Objective:Although the average depressed patient benefits moderately from cognitive-behavioral therapy (CBT) or pharmacotherapy, some experience divergent outcomes. The authors tested frequencies, predictors, and moderators of negative and unusually ...

https://doi.org/10.1176/appi.ajp.2015.15040492

Video

Ultra-Low-Dose Buprenorphine as a Time-Limited Treatment for Severe Suicidal Ideation: A Randomized Controlled Trial

Publication date: 18 December 2015

Pages491–498

Objective:Suicidal ideation and behavior currently have no quick-acting pharmacological treatments that are suitable for independent outpatient use. Suicidality is linked to mental pain, which is modulated by the separation distress system through ...

https://doi.org/10.1176/appi.ajp.2015.15040535

Video

Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial

Publication date: 12 February 2016

Pages499–508

Objective:Major depressive disorder has been associated with dysregulation of the endogenous opioid system. The authors sought to determine whether opioid modulation achieved through administration of ALKS 5461, a combination of a μ- and κ-opioid partial ...

https://doi.org/10.1176/appi.ajp.2015.15070921

Perinatal Phosphatidylcholine Supplementation and Early Childhood Behavior Problems: Evidence for CHRNA7 Moderation

Publication date: 07 December 2015

Pages509–516

Objective:α7-Nicotinic receptors are involved in the final maturation of GABA inhibitory synapses before birth. Choline at levels found in the amniotic fluid is an agonist at α7-nicotinic receptors. The authors conducted a double-blind placebo-controlled ...

https://doi.org/10.1176/appi.ajp.2015.15091188

Common and Dissociable Mechanisms of Executive System Dysfunction Across Psychiatric Disorders in Youth

Publication date: 22 January 2016

Pages517–526

Objective:Disruption of executive function is present in many neuropsychiatric disorders. However, determining the specificity of executive dysfunction across these disorders is challenging given high comorbidity of conditions. Here the authors ...

https://doi.org/10.1176/appi.ajp.2015.15060725

Prefrontal GABA Levels Measured With Magnetic Resonance Spectroscopy in Patients With Psychosis and Unaffected Siblings

Publication date: 22 January 2016

Pages527–534

Objective:The authors sought to compare GABA levels in treated and untreated patients with psychosis with levels in their unaffected siblings and healthy control subjects, and to assess the effects of antipsychotic medications on GABA levels.Method:GABA+ ...

https://doi.org/10.1176/appi.ajp.2015.15020190